Editor's Choice | This Week in BMJ | Press releases
BMJ No 7122 Volume 315 Editorial Saturday 13 December 1997
The emerging role of statins in the prevention of coronary heart diseaseStatins are effective but we need better ways of assessing riskSee Paper (abstract only) p 1577 and Letters p 1615The Standing Medical Advisory Committee guidelines for the use of statins have ignited considerable debate in Britain, and similar discussions about the use of statins are, or soon will be, occurring in other countries. The crux of the controversy lies, on the one hand, in earnest efforts to prevent coronary heart disease by any effective means available and, on the other, in fiscal realism. Such controversy has been foreseeable since publication of three clinical trials showing that statins are highly effective in preventing heart disease. The British guidelines conservatively recommend statin treatment only for individuals with at least a 3% annual risk of coronary heart disease events - a threshold selected to minimise costs and focus on patients at highest risk. Ironically, the subsequent BMJ editorial criticised the guidelines for being fiscally irresponsible,(1) whereas other issued guidelines and much of the journal correspondence(2) call for the treatment of more, not fewer, individuals.(3) Three interrelated challenges confront efforts to determine the optimal use of statins: (a) sufficient definition of the benefits, costs, and risks of treatment based on data from randomised clinical trials; (b) innovative strategies to minimise treatment costs; and (c) improved methods for estimating individual patients' risk. It is now clear that treatment of hypercholesterolaemic patients with statins reduces the incidence of fatal and non-fatal myocardial infarctions by 30-35%.(4) These benefits are accompanied by fewer coronary revascularisation procedures and fewer strokes.(5) Additional potential benefits that have not yet been clearly shown include reductions in the incidence of anginal symptoms, congestive heart failure, disability, and unemployment and improved quality of life. Moreover, the cost effectiveness of statins in secondary prevention is comparable to, or better than, other standard preventive interventions.(6) Nevertheless, several important gaps in our knowledge remain. The quoted reduction in coronary heart disease produced by statins in patients with heart disease was achieved in studies in which many of the participants were smokers and were not receiving aspirin or ß blockers. Most of the benefit may have occurred in smokers receiving lipid therapy alone; conversely, statins may have produced additive or even synergistic effects in combination with non-lipid treatments like smoking cessation, aspirin, or ß blockers. The incremental benefit from statin therapy in patients already receiving other standard interventions needs to be quantified. Importantly, the cost effectiveness of statins in the treatment of individuals without clinical signs of cardiovascular disease has not been defined. Primary prevention is clearly less cost effective than secondary prevention because of the lower absolute risk of coronary heart disease, especially in the short term, in overtly healthy individuals. The paper by Caro et al in this issue (p 1577) is the third published analysis on the cost effectiveness of primary prevention with statins, and each comes to different conclusions.(7-9) Such analyses are necessarily complex and employ various models and assumptions at the discretion of the authors.(10) Also, some cost effectiveness research is supported directly by pharmaceutical companies, which have much to gain from increasing statin markets.(6,7) Therefore consensus on this issue will be difficult. Cholesterol lowering treatment in the elderly, for whom little clinical trial data exist, presents additional questions. Older people are at high risk of coronary heart disease because of age, yet elderly people with low cholesterol values do not necessarily have less heart disease or survive longer than their hypercholesterolaemic counterparts.(11,12) Finally, with respect to safety, deaths from certain non-coronary causes, including cancer, accidents, and suicides, have been increased in some trials, and potential mechanisms are still being investigated.(13-15) Also, non-coronary morbidity outcomes have not been fully reported, and long term follow up has not yet accrued. The purchase price of statins is the single largest determinant of the cost of lipid lowering therapy. Therefore, when healthcare resources are fixed, drug price very directly affects our ability to prevent coronary heart disease. If purchasing leverage is used to drive competitive bidding for formulary contracts, considerable costs savings may be achieved (p 1616).(2) For example, the Veterans Health Administration has obtained a price reduction of nearly half (16,17) that of the typical purchase price of simvastatin in America (which is similar to that in Britain). Clinical decisions about which patients to treat essentially entail estimating the risk of coronary heart disease. That risk is quite high in patients with clinically apparent coronary artery obstruction, and three quarters of such individuals will die from ischaemic heart disease. We agree with the guidelines regarding hypercholesterolaemic patients with atherosclerotic disease outside the coronary arteries (aortic, peripheral, or carotid). Their risk of coronary heart disease is also high and proportional to the severity of their atherosclerosis.(18-21) Difficulties and differences of opinion arise over the treatment of apparently healthy people, and for them we can and must improve ways of assessing risk. The more accurately coronary heart disease is predicted, the more efficiently our treatment can be targeted, and the more coronary events we will prevent at the least cost and risk. This greater precision can be achieved by systematic and quantitative consideration of multiple risk factors. Total cholesterol is not the best lipid parameter - we recommend the ratio of total cholesterol to high density lipoprotein (HDL) because this single number captures most of the value of the full lipid profile in most patients.(22) Moreover, change in the total cholesterol:HDL ratio with treatment correlates with benefit in coronary heart disease better than other lipid measures. Commendably, the Sheffield tables do quantify risk and, as well as cholesterol values, take into account age, gender, hypertension, current smoking, diabetes, and left ventricular hypertrophy on electrocardiography. However, we also know that early coronary heart disease in a first degree relative (before age 50 in men or 60 in women) increases an individual's risk and also helps to identify those with familial hyperlipidaemias. Other blood borne factors and genetic markers may soon be added to standard risk assessments.(22,23) Ultimately, the disease we are trying to predict causes morphological changes which may be imaged or otherwise measured, and this should lead us from indirect risk assessment to non-invasive measurement of the disease itself, atherosclerosis. Here, accumulating evidence is establishing the utility of detecting subclinical atherosclerosis by the ankle-brachial blood pressure index, carotid artery sonography, and detection of coronary calcifications.(24-27) The challenge is to offer doctors improved methods of risk stratification to use in their daily practice. Irrespective of these deliberations, prescriptions for statins have jumped in Britain, and during 1997 in America annual sales of cholesterol lowering drugs increased by a remarkable 29% to $3.7bn (£2.3bn) (International Marketing Services). The great popularity of statins is largely a result of their efficacy and tolerability. However, we should also be cautious with these powerful drugs, for the reasons discussed above. Moreover, the comparable ease of reducing cholesterol concentrations by pharmacological means should not substitute for multiple risk factor interventions, including non-pharmacological approaches to preventing coronary heart disease. Matthew F Muldoon
Assistant professor of medicine
Michael H Criqui
Professor
References
1 Freemantle N, Barbour R, Johnson R, Marchment M, Kennedy
A. The use of statins: a case of misleading priorities? BMJ
1997;315:826-8.
2 Use of statins [letters]. BMJ
1997;315:1615-20.
3 Pyorala K, De Backer G, Poole-Wilson P, Wood D on behalf of
the task force. Prevention of coronary heart disease in clinical
practice: recommendations of the task force of the European Society of
Cardiology, European Atherosclerosis Society, and European Society of
Hypertension. Eur Heart J 1994;15:1300-31.
4 Hebert P R, Gaziano J M, Chan K S, Hennekens C H. Cholesterol
lowering with statin drugs, risk of stroke, and total mortality.
JAMA 1997;278:313-21.
5 Crouse J R, Byington R P, Hoen H M, Furberg C D. Reductase
inhibitor monotherapy and stroke prevention. Arch Intern
Med 1997;157:1305-10.
6 Johannesson M, Jonsson B, Kjekshus J, Olsson A G, Pedersen T R,
Wedel H. Cost effectiveness of simvastatin treatment to lower
cholesterol levels in patients with coronary heart disease. N
Engl J Med 1997;336:332-6.
7 Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettit D, et
al for the West of Scotland Coronary Prevention Study Group. The West
of Scotland coronary prevention study: economic benefit analysis of
primary prevention with priavastatin. BMJ
1997;315:1577-82.
8 Pharoah P D P, Hollingworth W. Cost effectiveness of lowering
cholesterol concentration with statins in patients with and without
pre-existing coronary heart disease: life table method applied to
health authority population. BMJ 1996;312:1443-8.
9 Haq I U L, Ramsay L E, Pickin D M, Yeo W W, Jackson P R, Payne J N.
Lipid-lowering for prevention of coronary heart disease: what policy
now? Clin Sci 1996;91:399-413.
10 Yusuf S, Anand S. Cost of prevention: the case of lipid
lowering. Circulation 1996;39:1774-6.
11 Kronmal R A, Cain K C, Ye Z, Omenn G S. Total serum cholesterol
levels and mortality risk as a function of age. Arch Int
Med 1993;153:1065-73.
12 Weverling-Rijnsberger A W, Blauw G J, Lagaay A M, Knook D L,
Meinders A E, Westendorp R G. Total cholesterol and risk of mortality in
the oldest old. Lancet 1997;350:1119-23.
13 Muldoon M F, Marsland A, Flory J D, Rabin B S, Whiteside T L,
Manuck S B. Immune system differences in men with hypo- or
hypercholesterolemia. Clin Immunol Immunopathol
1997;84:145-9.
14 Muldoon M F, Flory J D, Marsland A, Manuck S B, Whiteside T L,
Rabin B S. Effects of lovastatin on the immune system. Am J
Cardiol 1997:80:1391-4.
15 Muldoon M F, Ryan C M, Flory J D, Matthews K A, Manuck S B. Effects
of cholesterol reduction on cognitive performance
Circulation 1997:96 (suppl 1):405.
16 Kizer K W, Ogden J E, Ray J E. Pharmacy benefits management in the
veterans health care system. Drug Benefits Trends
1997;9:24-7.
17 Patterson A A, Pierce R A, Powell A P. Prime vendor purchasing of
pharmaceuticals in the Veterans Affiairs health care system. Am
J Health-Syst Pharm 1995;52:1886-9.
18 Criqui M H, Langer R D, Fronek A, Feigelson H S, Klauber M K,
McCann T J, et al. Mortality over a period of 10 years in patients with
peripheral arterial disease. N Engl J Med
1992;326:381-6.
19 Salonen J T, Salonen R. Ultrasonographically assessed carotid
morphology and the risk of coronary heart disease.
Arteriosclerosis and Thrombosis 1991;11:1245-9.
20 Norris J W, Zhu C Z, Bornstein M D, Chambers B R. Vascular risks of
asymptomatic carotid stenosis. Stroke 1991;22:1485-90.
21 McKenna M, Woflson S, Kuller L. The ratio of ankle and arm
arterial pressure as an independent predictor of mortality.
Atherosclerosis 1991;87:119-28.
22 Kinosian B, Glick H, Garland G. Cholesterol and coronary heart
disease: predicting risks by levels and ratios. Ann Intern
Med 1994;121:641-7.
23 Kinosian B, Glick H, Preiss L, Puder K L. Cholesterol and
coronary heart disease: predicting risks in men by changes in levels
and ratios. J Investig Med 1995;43:443-50.
24 Kuller L H, Shemanski L, Psaty B M, Borhani N O, Gardin J, Haan
M N, et al. Subclinical disease as an independent risk factor for
cardiovascular disease. Circulation 1995;92:720-6.
25 Chimovitz M B, Weiss D G, Cohen S T, Starling M R, Hobson R W, and
the Veterans Affairs Cooperative Study Group 167. Cardiac prognosis of
patients with carotid stenosis and no history of coronary artery
disease. Stroke 1994;25:759-65.
26 Newman A B, Sutton-Tyrrell K, Vogt, M T, Kuller L H. Morbidity and
mortality in hypertensive patients with a low ankle/arm blood pressure
index. JAMA 1993;270:487-9.
27 Wong N D, Detrano R C, Abrahamson D, Tobis J M, Gardin J M.
Coronary artery screening by electron beam computed tomography. Facts,
controversy, and future. Circulation 1995;92:632-6.
Home | Current issue | Past issues | Classified ads | Career Focus | Feedback Collections | About this site | About the BMJ | BMA | Medline
|